Ironwood Pharmaceuticals shares jumped 27% after the company issued guidance calling for a substantial increase in full-year 2026 revenue, driven by continued growth of LINZESS demand in the United States. In its most recent quarter, Ironwood delivered revenue of $122.06 million, comfortably surpassing analysts’ estimates of $74.22 million, and reported earnings per share of $0.24 versus consensus expectations of $0.09. Management highlighted robust prescription trends for its flagship product, noting double-digit volume gains over the prior quarter, and provided an update on its development pipeline, advancing two mid-stage gastrointestinal candidates with top-line data anticipated in the coming year.

The stock traded more than 39 million shares on Friday, reaching a new 52-week high following a rating upgrade from hold to strong-buy by Zacks Research. Ironwood’s average analyst consensus remains at hold, with an average target price equivalent to roughly 2% above current levels. Over the past quarter, several institutional investors positioned around the company: Integrated Wealth Concepts increased its stake by 21.4% to 19,295 shares, BNP Paribas Financial Markets grew its holding by 83.2% to 34,331 shares, and new positions were established by McAdam LLC and Vise Technologies, each deploying approximately $40,000. The company’s market capitalization stands at $694.6 million, with a price-to-earnings ratio of 26.7 and a beta of 0.18.